Development of the method to evaluate and predict comorbidities in advanced heart failure

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K17580
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 53020:Cardiology-related
• Research Institution: Okayama University (2020-2021); National Cardiovascular Center Research Institute (2019)
• Principal Investigator: iwasaki keiichiro 岡山大学, 大学病院, 医員 (40815346)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 心不全 / 重症心不全 / 腎不全 / サルコペニア

Outline of Final Research Achievements

Heart failure is a progressive condition in which the heart muscle couldn't pump enough blood. Advanced heart failure is a form of heart failure which has progressed to the most serious stage. Heart transplantation and implantable ventricular assist device revolutionized the management of advanced heart failure and drastically improved its survival. However, advanced heart failure is frequently complicated with comorbidities, such as renal dysfunction, hepatic dysfunction, pulmonary vascular failure, and sarcopenia. These comorbidities are known to worsen the morbidity and mortality in advanced heart failure, but the method of evaluation and prediction has not been well established. The current study revealed that urinary creatinine, sarcopenia indicator, and platelet count are associated with mortality or bleeding event in advanced heart failure.

Free Research Field

心不全

Academic Significance and Societal Importance of the Research Achievements

心不全患者では、全身への血の流れが悪くなることなどによる、全身の筋肉量の減少が多くの方で起こり、サルコペニアと呼ばれています。サルコペニアの標準的な評価方法はX線による被爆を伴いますが、尿クレアチニン総排泄量は尿検査だけで全身の筋肉量を推定することの出来る簡便な指標です。本研究により、重症心不全患者においても尿クレアチニン総排泄量から筋肉量を推定することが出来き、植込型補助人工心臓の手術後の経過を予測するのに有用であることが示されました。